Convection-enhanced selective excitotoxic ablation of the neurons of the globus pallidus internus for treatment of parkinsonism in nonhuman primates.
暂无分享,去创建一个
[1] E. Oldfield,et al. Reversal of experimental parkinsonism by using selective chemical ablation of the medial globus pallidus. , 1999, Journal of neurosurgery.
[2] A. Lang,et al. Posteroventral medial pallidotomy in advanced Parkinson's disease. , 1997, Advances in neurology.
[3] A. Benabid,et al. Opposite motor effects of pallidal stimulation in Parkinson's disease , 1998, Annals of neurology.
[4] M. Heyes,et al. Quinolinic Acid In Vivo Synthesis Rates, Extracellular Concentrations, and Intercompartmental Distributions in Normal and Immune‐Activated Brain as Determined by Multiple‐Isotope Microdialysis , 1998, Journal of neurochemistry.
[5] K. Mewes,et al. Visual fields in patients with posterior GPi pallidotomy , 1998, Neurology.
[6] O. Hornykiewicz,et al. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. , 1960, Parkinsonism & related disorders.
[7] J. Bronstein,et al. Delayed internal capsule infarctions following radiofrequency pallidotomy. Report of three cases. , 1997, Journal of neurosurgery.
[8] E. Oldfield,et al. Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. , 1997, Journal of neurosurgery.
[9] M. Heyes,et al. Quantification of Local De Novo Synthesis Versus Blood Contributions to Quinolinic Acid Concentrations in Brain and Systemic Tissues , 1997, Journal of neurochemistry.
[10] R. Turner,et al. Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1‐year results of a pilot study , 1996, Annals of neurology.
[11] W. Pardridge,et al. Pharmacokinetics and blood-brain barrier transport of [3H]-biotinylated phosphorothioate oligodeoxynucleotide conjugated to a vector-mediated drug delivery system. , 1996, The Journal of pharmacology and experimental therapeutics.
[12] P F Morrison,et al. Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. , 1995, Journal of neurosurgery.
[13] J. A. Obeso,et al. Restoration of thalamocortical activity after posteroventral pallidotomy in Parkinson's disease , 1994, The Lancet.
[14] P F Morrison,et al. Convection-enhanced delivery of macromolecules in the brain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[15] P F Morrison,et al. High-flow microinfusion: tissue penetration and pharmacodynamics. , 1994, The American journal of physiology.
[16] W. Pardridge,et al. Brain drug delivery and blood–Brain barrier transport , 1993 .
[17] M. Demitrack,et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. , 1992, Brain : a journal of neurology.
[18] P F Morrison,et al. Quantitative Examination of Tissue Concentration Profiles Associated with Microdialysis , 1992, Journal of neurochemistry.
[19] J. Penney,et al. Excitatory amino acid binding sites in the basal ganglia of the rat: A quantitative autoradiographic study , 1992, Neuroscience.
[20] M. Hariz,et al. Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. , 1992, Journal of neurosurgery.
[21] R. Schwarcz,et al. Blood–Brain Barrier Transport of Kynurenines: Implications for Brain Synthesis and Metabolism , 1991, Journal of neurochemistry.
[22] G. Forloni,et al. Neurodegenerative Effects Induced by Chronic Infusion of Quinolinic Acid in Rat Striatum and Hippocampus , 1991, The European journal of neuroscience.
[23] R. Kurlan,et al. Oral levodopa dose‐response study in MPTP‐induced hemiparkinsonian monkeys: Assessment with a new rating scale for monkey parkinsonism , 1991, Movement disorders : official journal of the Movement Disorder Society.
[24] R Langer,et al. New methods of drug delivery. , 1990, Science.
[25] H. Bergman,et al. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. , 1990, Science.
[26] A. Graybiel. Neurotransmitters and neuromodulators in the basal ganglia , 1990, Trends in Neurosciences.
[27] M. Delong,et al. Primate models of movement disorders of basal ganglia origin , 1990, Trends in Neurosciences.
[28] G. E. Alexander,et al. Functional architecture of basal ganglia circuits: neural substrates of parallel processing , 1990, Trends in Neurosciences.
[29] C. Marsden. Parkinson's disease , 1940, The Lancet.
[30] J. Penney,et al. The functional anatomy of basal ganglia disorders , 1989, Trends in Neurosciences.
[31] M. Luquin,et al. Effect of the NMDA antagonist MK-801 on MPTP-induced parkinsonism in the monkey , 1989, Neuropharmacology.
[32] S. Markey,et al. Quantification of quinolinic acid in rat brain, whole blood, and plasma by gas chromatography and negative chemical ionization mass spectrometry: effects of systemic L-tryptophan administration on brain and blood quinolinic acid concentrations. , 1988, Analytical biochemistry.
[33] D. Jacobowitz,et al. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1986, Life sciences.
[34] R. Schwarcz,et al. Quinolinic Acid Phosphoribosyltransferase in Rat Brain , 1985, Journal of neurochemistry.
[35] D. Jacobowitz,et al. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. , 1983, Proceedings of the National Academy of Sciences of the United States of America.
[36] C. Marsden,et al. SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASE , 1977, The Lancet.
[37] R. Langer,et al. Polymers for the sustained release of proteins and other macromolecules , 1976, Nature.
[38] Smith Bm,et al. An ambulatory activity monitor with solid state memory. , 1976 .
[39] J. D. Parkes,et al. "ON-OFF" EFFECTS IN PATIENTS WITH PARKINSON'S DISEASE ON CHRONIC LEVODOPA THERAPY , 1976, The Lancet.
[40] C. Patlak,et al. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. , 1975, The Journal of pharmacology and experimental therapeutics.
[41] C S Patlak,et al. Measurements of dog blood-brain transfer constants by ventriculocisternal perfusion. , 1975, The American journal of physiology.
[42] A. Prince,et al. HEPANOSTICON IN SCREENING FOR HBsAg , 1975, The Lancet.